Gilead reported 13% third-quarter product sales growth and 3% non-GAAP diluted earnings per share growth. Management increased 2026 product sales guidance by $900 million at the midpoint based on HIV product outperformance and forecast a steeper non-GAAP EPS decline, largely due to acquisitions.
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.
Metric | GILD | ABBV | MRK |
|---|---|---|---|
Price/Earnings (Normalized) | — | 33.38 | 109.17 |
Price/Book Value | 15.99 | — | 8.07 |
Price/Sales | 6.75 | 7.91 | 5.40 |
Price/Cash Flow | 14.18 | 22.21 | 16.42 |
Metric | GILD | ABBV | MRK |
|---|---|---|---|
Quick Ratio | 0.95 | 0.56 | 0.78 |
Current Ratio | 1.38 | 0.87 | 1.35 |
Interest Coverage | −1.78 | 5.20 | 3.33 |
Metric | GILD | ABBV | MRK |
|---|---|---|---|
Return on Assets (Normalized) | −0.60% | 16.61% | 2.53% |
Return on Equity (Normalized) | −1.77% | — | 7.02% |
Return on Invested Capital (Normalized) | 0.51% | 36.97% | 4.79% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|<VGj$cl$ | LOCK|P?B | $1T | |||
| Johnson & Johnson JNJ | LOCK|ghL?f& | LOCK|D% | $683B | |||
| AbbVie Inc ABBV | LOCK|HC$<csm | LOCK|Hv | $520B | |||
| Roche Holding AG ADR RHHBY | LOCK|#%s!Hb@G | LOCK|>K | $390B | |||
| Merck & Co Inc MRK | LOCK|g?KQHj | LOCK|Y< | $362B | |||
| Novartis AG ADR NVS | LOCK|HlZ&BTwb | LOCK|%hr | $305B | |||
| AstraZeneca PLC AZN | LOCK|xn$MlZf | LOCK|H%G | $287B | |||
| Amgen Inc AMGN | LOCK|@%@vSD<t | LOCK|%%v | $253B | |||
| Novo Nordisk AS ADR NVO | LOCK|@tjt<$y | LOCK|kcN | $180B |
United States